Building core strength through financial strategy
This article was originally published in Scrip
The CRO industry is full to the brim with private equity investment, with companies such as PRA International, ReSearch Pharmaceutical Services (RPS), INC Research, Medpace, Chiltern International and Theorem Clinical Research (formerly Omnicare Clinical Research) all benefiting from the investment injections of the cash rich. However, one CRO has been busily reversing this strategy, by investing in biopharma companies, for the last decade.
You may also be interested in...
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"